Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) Equity Ratio (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Equity Ratio for 4 consecutive years, with 0.7 as the latest value for Q2 2025.

  • On a quarterly basis, Equity Ratio fell 2.59% to 0.7 in Q2 2025 year-over-year; TTM through Jun 2025 was 0.7, a 2.59% decrease, with the full-year FY2024 number at 0.7, up 6.16% from a year prior.
  • Equity Ratio was 0.7 for Q2 2025 at Centessa Pharmaceuticals, down from 0.73 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.82 in Q1 2022 to a low of 0.66 in Q4 2023.
  • A 4-year average of 0.74 and a median of 0.73 in 2025 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: dropped 13.33% in 2023, then rose 19.1% in 2024.
  • Centessa Pharmaceuticals' Equity Ratio stood at 0.76 in 2022, then decreased by 13.33% to 0.66 in 2023, then grew by 6.16% to 0.7 in 2024, then increased by 0.68% to 0.7 in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Equity Ratio are 0.7 (Q2 2025), 0.73 (Q1 2025), and 0.7 (Q4 2024).